Overview
Why This Class Changes Outcomes
Sodium–glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose, but their most consequential effects are often cardiovascular and renal.
NCLEX-RN
NCLEX-RN
Sodium–glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose, but their most consequential effects are often cardiovascular and renal. They are used for type 2 diabetes, heart failure, and chronic kidney disease (CKD), depending on the individual drug and indication. Heart failure and CKD benefits extend to people without diabetes. The class works independently of pancreatic insulin secretion. That matters clinically: an SGLT2 inhibitor alone has little intrinsic hypoglycaemia risk, and its cardiorenal benefit can persist even when reduced kidney function makes its glucose-lowering effect modest. For a person with type 2 diabetes and CKD, an SGLT2 inhibitor may be selected even when A1C is already at target. The goal is not simply a lower A1C; it is slower CKD progression and fewer cardiovascular events.
Unlock full lesson + practice questions
9 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this NCLEX-RN pathway. You can still explore topic-filtered questions from the bank hubs below.